Immune microenvironment in different molecular subtypes of ductal breast carcinoma

• Published in: Breast cancer research and treatment 2021-01, Vol.185 (2), p.261-279
• Main Authors: Sadeghalvad, Mona, Mohammadi-Motlagh, Hamid-Reza, Rezaei, Nima
• Format: Article
• Language: English
• Subjects: Antitumor agents; Biomarkers, Tumor; Breast cancer; Breast carcinoma; Breast Neoplasms - genetics; Breast Neoplasms - immunology; Cancer research; Carcinoma, Ductal; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Cytotoxicity; Development and progression; ErbB-2 protein; Female; Helper cells; Histocompatibility antigen HLA; Humans; Immune system; Immunity, Cellular; Immunoregulation; Invasiveness; Killer cells; Lymphocytes T; Macrophages; Medical colleges; Medical prognosis; Medicine; Medicine & Public Health; Oncology; Prognosis; Review; T cells; Tumor cells; Tumor Microenvironment
• ISSN: 0167-6806; 1573-7217
• DOI: 10.1007/s10549-020-05954-2

Purpose Ductal breast carcinoma as a heterogeneous disease has different molecular subtypes associated with clinical prognosis and patients’ survival. The role of immune system as a consistent part of the tumor microenvironment (TME) has been documented in progression of ductal breast carcinoma. Here, we aimed to describe the important immune cells and the immune system-associated molecules in Ductal Carcinoma In situ (DCIS) and Invasive Ductal Carcinoma (IDC) with special emphasis on their associations with different molecular subtypes and patients’ prognosis. Results The immune cells have a dual role in breast cancer (BC) microenvironment depending on the molecular subtype or tumor grade. These cells with different frequencies are present in the TME of DCIS and IDC. The presence of regulatory cells including Tregs, MDSC, Th2, Th17, M2 macrophages, HLADR − T cells, and Tγδ cells is related to more immunosuppressive microenvironment, especially in ER − and TN subtypes. In contrast, NK cells, CTL, Th, and Tfh cells are associated to the anti-tumor activity. These cells are higher in ER + BC, although in other subtypes such as TN or HER2 + are associated with a favorable prognosis. Conclusion Determining the specific immune response in each subtype could be helpful in estimating the possible behavior of the tumor cells in TME. It is important to realize that different frequencies of immune cells in BC environment likely determine the patients’ prognosis and their survival in each subtype. Therefore, elucidation of the distinct immune players in TME would be helpful toward developing targeted therapies in each subtype.